CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that Sujay Kango has joined the company as executive vice president, chief commercial officer and Winston “K.C.” Lam has joined as executive vice president, general counsel. Mr. Kango and Mr. Lam each bring more than 20 years of experience in the pharmaceutical industry, including expertise in oncology and hematology, and have played key roles in building successful companies and commercial organizations. Both Mr. Kango and Mr. Lam will report to Adelene Perkins, chair, president and chief executive officer at Infinity.
“The addition of Sujay to our executive team is an important advancement for Infinity as we continue to build our commercial capabilities in preparation for the potential launch of duvelisib,” said Ms. Perkins. “We look forward to benefitting from Sujay’s experience in both large and emerging companies, as well as his deep understanding of the hematology-oncology market.”
“K.C. has an extensive record of legal and corporate development accomplishments. He will be an outstanding member of our executive leadership team in helping us achieve our mission of building a fully integrated biotechnology company with a sustainable pipeline. We are thrilled to have both Sujay and K.C. join Infinity at this exciting time in the development of duvelisib and the company,” Ms. Perkins continued.
Prior to joining Infinity, Mr. Kango most recently served as vice president, global marketing, sales operations (and business analytics) at Onyx Pharmaceuticals, an Amgen subsidiary, where he led the global Onyx proteasome inhibitor franchise, including Kyprolis® and oprozomib and co-chaired the Onyx-Bayer executive committee responsible for oversight of the companies’ global kinase inhibitor franchise. Prior to Onyx, he held several leadership positions at Merck & Co., including vice president, hepatitis franchise and vice president, oncology integrated business unit. Prior to Merck, Mr. Kango held various commercial and marketing roles of increasing responsibility at Johnson & Johnson and Schering-Plough. Mr. Kango earned a B.S. in Microbiology and an MBA from McNeese State University.
Prior to joining Infinity, Mr. Lam served as executive vice president, business development and chief legal officer at Caris Life Sciences. In this role, Mr. Lam was responsible for business development, reimbursement strategy and medical policy, pharmaceutical services and legal affairs. Prior to Caris, Mr. Lam served as group vice president and associate general counsel at Schering-Plough where he served as chief legal counsel for the Global Pharmaceuticals Business Unit which represented 75 percent of Schering-Plough’s total revenues. He also played active roles in the management of the company’s key strategic alliances and in executing its licensing, merger and acquisition strategy. Prior to Schering-Plough, Mr. Lam held various roles of increasing responsibility in business development and law at McKesson Corporation and at Baxter Healthcare Corporation. He earned a B.A. from Carleton College, an MBA from University of Chicago, Booth School of Business and a J.D. from Cornell University Law School.
About Infinity Pharmaceuticals, Inc.
Infinity is an innovative biopharmaceutical company dedicated to discovering, developing and delivering best-in-class medicines to people with difficult-to-treat diseases. Infinity combines proven scientific expertise with a passion for developing novel small molecule drugs that target emerging disease pathways. For more information on Infinity, please refer to the company’s website at www.infi.com.
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 including those regarding the Company’s expectations about the potential commercialization of duvelisib, including a potential launch, and the anticipated contributions of Sujay Kango and Winston “K.C.” Lam. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the company’s current expectations, including, for example, that there is guarantee duvelisib will successfully complete necessary preclinical and clinical development phases, or gain regulatory approval, that Infinity’s strategic collaboration with AbbVie will continue, and other risks described in greater detail under the caption “Risk Factors” included in Infinity’s annual report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 24, 2015, and other filings filed by Infinity with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Infinity expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.